RG7287
RG7287 is an activating antibody inhibitor targeting human CDCP1. RG7287 prevents the loss of contact inhibition caused by the co-transformation of NIH3T3 cells with CDCP1 and Src in focus formation assays. RG7287 inhibits tumor cell proliferation and leads to a significant reduction in CDCP1 levels[1].
Product Specifications
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
Others
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
97.666
Smiles
[RG7287]
Precautions
H302, H315, H319, H335
References & Citations
[1]Gwendlyn Kollmorgen, et al. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol. 2013 Dec;7 (6) :1142-51.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1339141-01 0.02 mg (E-Coli)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1)
Ask
View Details 
MBS1339141-02 0.1 mg (E-Coli)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1)
Ask
View Details MBS1339141-03 0.02 mg (Yeast)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1)
Ask
View Details MBS1339141-04 0.1 mg (Yeast)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1)
Ask
View Details MBS1339141-05 0.02 mg (Baculovirus)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1)
Ask
View Details MBS1339141-06 0.02 mg (Mammalian-Cell)
Recombinant Gloeobacter violaceus NAD (P)H-quinone oxidoreductase subunit K 1 (ndhK1)
Ask
View Details